Cyclosporine and ketoconazole can be used together, but this combination carries a moderate drug interaction that requires careful monitoring and likely dosage adjustment. Ketoconazole significantly increases cyclosporine blood levels by inhibiting the CYP3A4 enzyme system that metabolizes cyclosporine, potentially leading to toxicity. Additionally, both drugs can damage the kidneys, creating an additive risk of renal dysfunction.
The FDA labels for both cyclosporine and ketoconazole document this interaction as clinically significant. According to FDA drug labeling data, ketoconazole increases cyclosporine concentrations via inhibition of cytochrome P450 3A4 (CYP3A4), the primary metabolic pathway for cyclosporine. The interaction severity is classified as moderate, meaning it has the potential to cause clinical harm but is manageable with appropriate dose modification and monitoring.
Both drugs are nephrotoxic (toxic to the kidneys), and their combined use can potentiate renal dysfunction—meaning the risk of kidney damage is higher when taken together than when either drug is used alone. The FDA labeling recommends that cyclosporine dosage be adjusted downward when ketoconazole is initiated, and that cyclosporine trough levels (the minimum concentration in the blood before the next dose) be monitored closely.
To understand why this interaction matters clinically, it helps to understand how both drugs are processed by your body.
Cyclosporine Metabolism: Cyclosporine is a calcineurin inhibitor used to prevent organ rejection after transplantation and to treat autoimmune diseases like rheumatoid arthritis and certain forms of severe dermatitis. It is highly lipophilic (fat-soluble) and undergoes extensive first-pass hepatic metabolism. Approximately 90% of cyclosporine is metabolized by the CYP3A4 enzyme in the liver. The drug has a narrow therapeutic window, meaning the difference between an effective dose and a toxic dose is relatively small. Cyclosporine trough levels must be maintained within a specific range—typically 100–400 ng/mL, depending on the clinical indication and time after transplant—to balance efficacy with safety.
Ketoconazole's Role as a CYP3A4 Inhibitor: Ketoconazole is a triazole antifungal agent used to treat systemic fungal infections. It is a potent inhibitor of CYP3A4, one of the most important drug-metabolizing enzymes in the human body. When ketoconazole is present, it occupies the active site of CYP3A4, effectively blocking the enzyme's ability to metabolize cyclosporine. This leads to a dramatic reduction in cyclosporine clearance from the body.
The Resulting Accumulation: Clinical studies have demonstrated that ketoconazole can increase cyclosporine blood levels by 50–100% or more. A 1993 study published in clinical transplantation literature showed that coadministration of ketoconazole reduced cyclosporine requirements by approximately 50–80%, depending on the dose of ketoconazole used. This accumulation occurs within days of starting ketoconazole and can persist throughout the duration of antifungal therapy.
Additive Nephrotoxicity: Both cyclosporine and ketoconazole can cause dose-dependent kidney injury. Cyclosporine causes renal vasoconstriction and can lead to chronic kidney disease with prolonged use. Ketoconazole, while generally well-tolerated, can impair renal function in susceptible patients, especially those with preexisting kidney disease. When used together, the risk of acute kidney injury (AKI) or worsening chronic kidney disease (CKD) increases substantially.
Not all patients taking cyclosporine who require ketoconazole are at equal risk for serious adverse effects. Several patient factors increase vulnerability:
A 58-year-old woman is 3 years post-heart transplant and stable on cyclosporine 3 mg/kg twice daily, with trough levels consistently in the range of 120–150 ng/mL. Her baseline serum creatinine is 1.3 mg/dL (eGFR approximately 55 mL/min/1.73m²), indicating mild CKD. She develops invasive candidiasis (a serious fungal infection) and her cardiologist consults with infectious disease, who recommends ketoconazole 200 mg daily as part of her antifungal regimen.
Without dose adjustment, her cyclosporine levels would likely rise to 250–300 ng/mL within 5–7 days due to CYP3A4 inhibition by ketoconazole. At these elevated levels, she risks acute kidney injury, hepatotoxicity, and neurological side effects (tremor, headache, confusion). The appropriate management here is: (1) reduce cyclosporine dose by 50–75% at the time ketoconazole is initiated; (2) measure cyclosporine trough levels 3–5 days after ketoconazole starts; (3) monitor serum creatinine and potassium twice weekly; and (4) ensure adequate hydration. Once the infection clears and ketoconazole is stopped, cyclosporine is titrated back up to original doses over several weeks with repeat level monitoring.
A 72-year-old man with moderate rheumatoid arthritis is on cyclosporine 2.5 mg/kg daily for disease control and is responding well, with stable trough levels around 100 ng/mL. His baseline creatinine is 1.1 mg/dL (eGFR ~65 mL/min/1.73m²). He develops onychomycosis (fungal toenail infection) and his dermatologist prescribes ketoconazole 200 mg daily for 6 months. Additionally, he reports taking over-the-counter ibuprofen 400 mg three times weekly for joint pain.
This patient is at significant risk: (1) he is older with borderline renal function; (2) he is taking an NSAID, which further reduces renal blood flow; (3) ketoconazole will reduce cyclosporine clearance. A safer approach involves: (1) calculating a 25–50% dose reduction in cyclosporine (e.g., from 2.5 to 1.5 mg/kg daily); (2) discontinuing ibuprofen or switching to acetaminophen; (3) measuring cyclosporine trough level at day 5 of ketoconazole therapy; (4) checking serum creatinine, potassium, and magnesium at baseline and weekly for the first 3 weeks; (5) ensuring adequate fluid intake (2–3 liters daily unless contraindicated); and (6) scheduling a follow-up with his rheumatologist and nephrologist at 2 weeks to reassess kidney function and rheumatologic control.
For Patients:
For Healthcare Providers:
Seek immediate medical attention or contact your doctor right away if you experience:
If you are on cyclosporine, ketoconazole is not the only medication that requires caution. Other CYP3A4 inhibitors—including clarithromycin, diltiazem, and certain protease inhibitors—can cause similar interactions. Similarly, cyclosporine and fluconazole also interact, though typically less severely than with ketoconazole. It is also important to understand interactions between cyclosporine and NSAIDs, as NSAIDs amplify nephrotoxicity. For patients on long-term cyclosporine, cyclosporine and tacrolimus should never be coadministered due to overlapping toxicity.
If you are taking cyclosporine, ketoconazole, or both, ensure your complete medication list is reviewed by your pharmacist and physician. Use checkdruginteractions.com to check your full medication profile against our FDA-sourced database of over 250,000 drug labels. A few minutes of verification now can prevent serious drug interactions and protect your health. Enter all your medications—including over-the-counter drugs, supplements, and herbal products—to get a comprehensive interaction report customized to your specific regimen.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.